Professional Documents
Culture Documents
HOPECARDIS 2017 2
OUTLINES
I. INTRODUCTION
III. SUMMARY
HOPECARDIS 2017 3
OUTLINES
I. INTRODUCTION
III. SUMMARY
HOPECARDIS 2017 4
INTRODUCTION
HOPECARDIS 2017 5
independently associated
INTRODUCTION with 2x risk of all cause
mortality in women and
1.5x in men
3% in adults
≥ 20 y.o
33.5 million
(2010)
HOPECARDIS 2017 6
FIVE DOMAINS OF AF MANAGEMENT
Acute rate &
• Drugs
rhythm control
Managing • Lifestyle changes, treatment of
precipitating factors underlying CVD conditions
I. INTRODUCTION
III. SUMMARY
HOPECARDIS 2017 8
Recommendation in AF patients
HOPECARDIS 2017 10
2012 Guideline 2016 Guideline
Screening
Pulse taking followed by Pulse taking or ECG in patients > 65 y.o
ECG, in patients ≥ 65 y.o I-B
ECG recording followed by continous ECG, at
least 72 hours (TIA or stroke patients)
I-B
ECG monitoring before therapy ( in AHRE
patients) IIa-B
Long-term non invasive ECG monitors or
implanted loop recorders in stroke patients
IIa-B
Systematic ECG in >75 y.o or high stroke risk.
IIb-B
HOPECARDIS 2017 11
RECOMMENDATION FOR DIAGNOSIS
HOPECARDIS 2017 12
2012 Guideline 2016 Guideline
Diagnosis
ECG documentation to establish
diagnosis I-B
A full cardiovasculer evaluation and
assesment of concomittant condition
for all patients I-B
Transthoracic echocardiography for all
patients I-C
Long-term ECG monitoring in selected
patients IIa-C
HOPECARDIS 2017 13
RECOMMENDATION FOR
ATRIAL FIBRILLATION MANAGEMENT
HOPECARDIS 2017 14
2012 Guideline 2016 Guideline
EHRA symptom scale
NONE Modified EHRA symptom scale for
clinical practice and research
I-C
HOPECARDIS 2017 15
2012 Guideline 2016 Guideline
AF + Valvular Heart Disease
NONE Early mitral valve surgery for severe
MR and preserved LV function
IIa-C
Mitral valvulotomy for asymptomatic
patients with severe MS & suitable
valve IIa-C
HOPECARDIS 2017 16
2012 Guideline 2016 Guideline
AF + Respiratory diseases
NONE Correction of hypoxaemia and
acidosis IIa-C
HOPECARDIS 2017 17
2012 Guideline 2016 Guideline
AF + Kidney Disease
NONE Assessment of creatinine clearance
I-A
HOPECARDIS 2017 18
RECOMMENDATION FOR
ATRIAL FIBRILLATION MANAGEMENT
HOPECARDIS 2017 19
2012 Guideline 2016 Guideline
Prediction of Stroke and Bleeding Risk
CHA2DS2-VASc The CHA2DS2-VASc score for stroke risk
score for stroke prediction
IIa-C
risk prediction
Bleeding risk scores to identify modifiable
risk factors for major bleeding.
IIa-B
Biomarkers (high-sensitivity troponin and
natriuretic peptide) to refine stroke and
bleeding risk IIa-B
HOPECARDIS 2017 20
2012 Guideline 2016 Guideline
Stroke Prevention
Antithrombotic for all AF patients OAC for all male with a CHA2DS2-VASc
except low risk or contraindication score > 2 ; 1 I-A II a - B
The choice antithrombotic based Oral anticoagulation, for female with a
upon risk of thromboembolism and CHA2DS2-VASc score ≥ 3 ; 2
bleeding I-A II a - B
CHA2DS2-VASc score of 0, no VKA (INR 2.0–3.0 or higher) for patients
antithrombotic with moderate-to-severe MS or
mechanical heart valves. I- B
CHA2DS2-VASc score ≥ 2 ; NOAC is recommended in preference to
OAC (I – A) a VKA I-A
CHA2DS2-VASc score of 1 ; Patients with VKA, keep time in
OAC (IIa – A) therapeutic range (TTR) as high as
possible and closely monitored. I-A
Female < 65 y.o, lone AF, CHA2DS2- Patients with VKA, considered for NOAC
VASc score of 1 : no antithrombotic treatment II b - A
HOPECARDIS 2017 21
2012 Guideline 2016 Guideline
Stroke Prevention
Antithrombotic for all AF Patients with VKA, TTR should
patients except low risk or be kept as high as possible &
contraindication closely monitored.
I-A
The choice antithrombotic Patients with VKA may be
based upon risk of considered for NOAC treatment
thromboembolism and IIb-A
bleeding
CHA2DS2-VASc score of 0, no Avoid combinations of OAC &
antithrombotic platelet inhibitors III-B
HOPECARDIS 2017 22
2012 Guideline 2016 Guideline
Stroke Prevention
Dabigatran 150 mg b.i.d is prefer Anticoagulant or antiplatelet
than 110 mg except for age ≥ 80, therapy is not recommended for
using of interacting drugs, HAS-
stroke prevention (without
BLED score ≥ 3, CrCl 30 – 49 ml/min
another risk factor)
III-B
Rivaroxaban dose 20 mg o.d id
Antiplatelet monotherapy is not
prefer than 15 mg o.d. Latter dose
reccomend for HAS-BLED ≥ 3, CrCl
recommended for stroke
30 – 49 ml/min prevention III-A
Stroke Prevention
AVOID combinations of oral anticoagulants & platelet III – B
inhibitors
OAC (1 month)
HOPECARDIS 2017 27
Antithrombotic after PCI in AF
HOPECARDIS 2017 28
2012 Guideline 2016 Guideline
Rate Control Therapy
NO EXPLANATION Beta-blockers, digoxin, diltiazem, or verapamil in patients
with LVEF ≥ 40%. I-B
Beta-blockers and/or digoxin in patients with LVEF <40%.I-B
Combination therapy if a single agent does not achieve the
necessary heart rate target. IIa-C
In patients with haemodynamic instability or severely
depressed LVEF, amiodarone for acute control of heart rate.IIb-B
In patients with permanent AF, antiarrhythmic drugs should
not routinely be used for rate control. III-A
A resting heart rate of <110 bpm as the initial heart rate
target IIa-B
Rhythm rather than rate control strategies as the preferred
in preexcited AF and AF during pregnancy. IIa-C
AV node ablation in patients unresponsive or intolerant to
intensive rate and rhythm control therapy IIa-B
29
HOPECARDIS 2017
Rate Control
Beta-blockers, digoxin, diltiazem, or verapamil ; LVEF ≥ I–B
40%.
Beta-blockers and/or digoxin ; LVEF <40%. I–B
Combination therapy if a single agent doesn’t achieve IIa – C
heart rate target.
In haemodynamic instability or severely depressed LVEF ; IIb – B
amiodarone (acute heart rate control)
In permanent AF; antiarrhythmic shouldn’t routinely be III – A
used
A resting heart rate of <110 bpm (initial target) IIa – B
Rhythm control as the preferred in preexcited AF & AF IIa – C
during pregnancy.
AV node ablation in patients unresponsive or intolerant to IIa – B
intensive rate & rhythm control therapyHOPECARDIS 2017 30
2012 Guideline 2016 Guideline
Rhythm Control Therapy
Indicated for symptom improvement I-B
NONE
HOPECARDIS 2017 34
2012 Guideline 2016 Guideline
Stroke prevention in patients designated for cardioversion
NONE Anticoagulation as soon as possible
IIa-B
Anticoagulation for a minimum of 3 weeks before
cardioversion I-B
TOE to exclude cardiac thrombus
I-B
Early cardioversion without TOE in AF <48 hours IIa-B
Stroke High risk ; long-term anticoagulant after
I-B
cardioversion. No risk factors ; anticoagulation for 4 weeks
Thrombus (+) ; anticoagulation at least 3 weeks.
I-C
Repeat TOE to ensure thrombus resolution before
cardioversion. IIa-C
Dronedarone, flecainide, propafenone, or sotalol for
prevention of recurrent symptomatic AF (normal left
I-A
ventricular function and left ventricular hypertrophy).
35
HOPECARDIS 2017
2012 Guideline 2016 Guideline
Stroke prevention in patients designated for cardioversion
Dronedarone for prevention of
Drodenarone for recurrent AF (I – A) recurrent symptomatic AF in patients
with stable CAD, and without HF I-A
Drodenarone not recomended for Amiodarone for prevention of
permanent AF recurrent symptomatic AF in HF
patients I-B
Short term (4 weeks) antiarrythmic ECG recording during the initiation of
therapy after cardioversion for AAD
selected patient IIa-B
AAD therapy is not recommended in
patients with prolonged QT interval or
those with significant sinoatrial node
disease or AV node dysfunction III-C
HOPECARDIS 2017
36
2012 Guideline 2016 Guideline
Stroke prevention in patients designated for cardioversion
Continuation of AAD therapy after AF ablation
IIa-B
ACE-Is, ARBs and beta-blockers for prevention of
new-onset AF in heart failure patients IIa-A
I. INTRODUCTION
III. SUMMARY
HOPECARDIS 2017 38
Ten Commandments of 2016 ESC
Guideline for AF management
Use ECG to screening & monitoring AF
HOPECARDIS 2017 41
HOPECARDIS 2017 42
Antithrombotic after ACS in AF patients
HOPECARDIS 2017 43
Long term rate control in AF
HOPECARDIS 2017 44
Acute heart rate control in AF
HOPECARDIS 2017 45
Rhythm control in AF recent onset
HOPECARDIS 2017 46
Long term rhythm control in AF patient
HOPECARDIS 2017 47
Recommendation for Screening
Recommendations CoR & LoE
HOPECARDIS 2017 48
Recommendation for diagnosis
CoR & LoE
Recommendations
ECG documentation to establish diagnosis I–B
HOPECARDIS 2017 49
Recommendation for AF Management
HOPECARDIS 2017 50
Recommendation for AF Management
AF + Valvular Heart Disease CoR & LoE
AF + respiratory diseases
Correction of hypoxaemia & acidosis IIa – C
Interrogation for clinical signs of OSA IIa – B
OSA treatment should be optimized IIa – B
HOPECARDIS 2017 51
Recommendation for AF Management
AF + kidney disease
Assess serum creatinine or creatinine clearance I–A
HOPECARDIS 2017 54
Recommendation for AF Management
HOPECARDIS 2017 61
HOPECARDIS 2017 62
Management of active bleeding in AF
patients receiving OAC
HOPECARDIS 2017 63
Priorities in the Management of AF
The Patient Care Pathway
Risk factors
Rhythm Control
Stroke prevention
Rate Control
HOPECARDIS 2017 64
2012 Guideline 2016 Guideline
Secondary Stroke Prevention
Heparin or LMWH immediately after an
NONE ischaemic stroke (III – A)
III-A
TIA or stroke while on anticoagulation,
reassessed adherence therapy & optimized
IIa-C
Moderate to severe ischaemic stroke while on
anticoagulation, anticoagulation should be
interrupted for 3–12 days IIa-C
In AF patients who suffer a stroke, aspirin for
prevention of secondary stroke until the
initiation or resumption of oral anticoagulation.
IIa-B
HOPECARDIS 2017 65
2012 Guideline 2016 Guideline
Secondary Stroke Prevention
NONE Systemic thrombolysis with rtPA is not
recommended if the INR is above 1.7
III-C
NOACs in preference to VKAs or aspirin
with a previous stroke I-B
HOPECARDIS 2017 71
Major mechanisms of atrial fibrillation
HOPECARDIS 2017 72
HOPECARDIS 2017 74
Timeline of atrial fibrillation management trials
HOPECARDIS 2017 75